BRCA1 and ovarian carcinoma: For example, BRCA1 and BRCA2 genes have been successfully targeted with poly (ADP-ribose) polymerase (PARP) inhibitors, leading to significant improvements in response rates and overall survival in patients with BRCA-mutated ovarian cancers [29].